# Phase 1 Leukemia, Myelogenous: 20 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1 for Leukemia, Myelogenous, Chronic, BCR-ABL Positive that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/leukemia-myelogenous-chronic-bcr-abl-positive

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909733 | Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | University of Wisconsin, Madison | Phase 1 | Not yet recruiting | High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909733) |
| August 11, 2026 | NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | University of Wisconsin, Madison | Phase 1 | Recruiting | Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758218) |
| June 16, 2026 | NCT07651878 | Vididencel in CML-CP Patients With MRD | Mendus | Phase 1 | Recruiting | CML (Chronic Myelogenous Leukemia) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651878) |
| April 14, 2026 | NCT07527221 | Safety and Tolerability of ZE74-0282 in Healthy Volunteers | Eilean Therapeutics AU Pty Ltd | Phase 1 | Recruiting | Healthy Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527221) |
| December 24, 2025 | NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | Stanford University | Phase 1 | Recruiting | GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302776) |
| November 28, 2025 | NCT07254793 | Prophylactic DLI-X for Leukemia Relapse After HCT | University of Arizona | Phase 1 | Recruiting | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254793) |
| May 29, 2025 | NCT06994676 | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Crossbow Therapeutics, Inc. | Phase 1 | Recruiting | High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994676) |
| April 1, 2025 | NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms... | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904066) |
| January 22, 2025 | NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants | Enliven Therapeutics | Phase 1 | Recruiting | CML (Chronic Myelogenous Leukemia), Chronic Phase CML | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06787144) |
| November 4, 2024 | NCT06672263 | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Myelogenous Leukemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672263) |
| July 31, 2024 | NCT06530810 | Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Myelogenous Leukemia, CML Chronic Phase, CML Accelerated Phase | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06530810) |
| October 18, 2023 | NCT06088888 | TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients | Shenzhen TargetRx Co., Ltd. | Phase 1 | Recruiting | Chronic Myelogenous Leukemia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06088888) |
| May 15, 2023 | NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | Florida International University | Phase 1 | Recruiting | Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large... | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05857969) |
| March 31, 2022 | NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia | Enliven Therapeutics | Phase 1 | Recruiting | Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05304377) |
| February 7, 2020 | NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic... | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04260022) |
| August 15, 2018 | NCT03630991 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic... | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03630991) |
| July 23, 2018 | NCT03595917 | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | Sponsor not shown (see the record) | Phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03595917) |
| May 23, 2018 | NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | University of Kansas Medical Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03533816) |
| October 31, 2017 | NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Fred Hutchinson Cancer Center | Phase 1 | Recruiting | Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03326921) |
| October 31, 2017 | NCT03326310 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | University of Chicago | Phase 1 | Recruiting | Chronic Myeloid Leukemia, Myelofibroses | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03326310) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Wisconsin, Madison | 2 |
| Enliven Therapeutics | 2 |
| Shenzhen TargetRx Co., Ltd. | 1 |
| Fred Hutchinson Cancer Center | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| University of Chicago | 1 |
| Mendus | 1 |
| Crossbow Therapeutics, Inc. | 1 |
| Eilean Therapeutics AU Pty Ltd | 1 |
| M.D. Anderson Cancer Center | 1 |
| Florida International University | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| Stanford University | 1 |
| National Cancer Institute (NCI) | 1 |
| University of Arizona | 1 |
| University of Kansas Medical Center | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| Canada | 2 |
| Australia | 2 |
| Norway | 1 |
| Belgium | 1 |
| France | 1 |
| Germany | 1 |
| Hungary | 1 |
| Israel | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Poland | 1 |
| South Korea | 1 |
| Spain | 1 |
| United Kingdom | 1 |
| Japan | 1 |
| China | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [EMS training centers in the United States](https://specstream.ai/data/businesses/ems-training-centers/united-states)
- [Abrasives suppliers in the United States](https://specstream.ai/data/businesses/abrasives-suppliers/united-states)
- [Packaging companies in the United States](https://specstream.ai/data/businesses/packaging-companies/united-states)
- [Engineering firms in the United States](https://specstream.ai/data/businesses/engineering-firms/united-states)
- [Advertising agencies in the United States](https://specstream.ai/data/businesses/advertising-agencies/united-states)
